Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,695 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevention of infections and fever to improve outcome in older patients with acute stroke (PRECIOUS): a randomised, open, phase III, multifactorial, clinical trial with blinded outcome assessment.
de Jonge JC, Sluis WM, Reinink H, Bath PM, Woodhouse LJ, Zweedijk B, van de Beek D, Aamodt AH, Alpers I, Ciccone A, Csiba L, Demotes J, Kõrv J, Kurkowska-Jastrzebska I, Dawson J, Macleod MR, Ntaios G, Poli S, Milionis H, Ricci S, Cenciarelli S, Candelaresi P, de Bruijn SF, Pathansali R, Krishnan K, Clarke B, Thomalla G, van der Worp HB; PRECIOUS investigators. de Jonge JC, et al. Among authors: dawson j. Lancet Reg Health Eur. 2023 Dec 1;36:100782. doi: 10.1016/j.lanepe.2023.100782. eCollection 2024 Jan. Lancet Reg Health Eur. 2023. PMID: 38074444 Free PMC article.
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial.
Wardlaw JM, Woodhouse LJ, Mhlanga II, Oatey K, Heye AK, Bamford J, Cvoro V, Doubal FN, England T, Hassan A, Montgomery A, O'Brien JT, Roffe C, Sprigg N, Werring DJ, Bath PM; Lacunar Intervention Trial-2 (LACI-2) Investigator Group. Wardlaw JM, et al. JAMA Neurol. 2023 Jul 1;80(7):682-692. doi: 10.1001/jamaneurol.2023.1526. JAMA Neurol. 2023. PMID: 37222252 Free PMC article. Clinical Trial.
Early versus Later Anticoagulation for Stroke with Atrial Fibrillation.
Fischer U, Koga M, Strbian D, Branca M, Abend S, Trelle S, Paciaroni M, Thomalla G, Michel P, Nedeltchev K, Bonati LH, Ntaios G, Gattringer T, Sandset EC, Kelly P, Lemmens R, Sylaja PN, Aguiar de Sousa D, Bornstein NM, Gdovinova Z, Yoshimoto T, Tiainen M, Thomas H, Krishnan M, Shim GC, Gumbinger C, Vehoff J, Zhang L, Matsuzono K, Kristoffersen E, Desfontaines P, Vanacker P, Alonso A, Yakushiji Y, Kulyk C, Hemelsoet D, Poli S, Paiva Nunes A, Caracciolo N, Slade P, Demeestere J, Salerno A, Kneihsl M, Kahles T, Giudici D, Tanaka K, Räty S, Hidalgo R, Werring DJ, Göldlin M, Arnold M, Ferrari C, Beyeler S, Fung C, Weder BJ, Tatlisumak T, Fenzl S, Rezny-Kasprzak B, Hakim A, Salanti G, Bassetti C, Gralla J, Seiffge DJ, Horvath T, Dawson J; ELAN Investigators. Fischer U, et al. Among authors: dawson j. N Engl J Med. 2023 Jun 29;388(26):2411-2421. doi: 10.1056/NEJMoa2303048. Epub 2023 May 24. N Engl J Med. 2023. PMID: 37222476 Free article. Clinical Trial.
Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
Sharma M, Molina CA, Toyoda K, Bereczki D, Bangdiwala SI, Kasner SE, Lutsep HL, Tsivgoulis G, Ntaios G, Czlonkowska A, Shuaib A, Amarenco P, Endres M, Yoon BW, Tanne D, Toni D, Yperzeele L, von Weitzel-Mudersbach P, Sampaio Silva G, Avezum A, Dawson J, Strbian D, Tatlisumak T, Eckstein J, Ameriso SF, Weber JR, Sandset EC, Goar Pogosova N, Lavados PM, Arauz A, Gailani D, Diener HC, Bernstein RA, Cordonnier C, Kahl A, Abelian G, Donovan M, Pachai C, Li D, Hankey GJ. Sharma M, et al. Among authors: dawson j. Lancet Neurol. 2024 Jan;23(1):46-59. doi: 10.1016/S1474-4422(23)00403-9. Lancet Neurol. 2024. PMID: 38101902 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 38589066
Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes.
Smith EE, Shoamanesh A, Xu L, Heenan L, Saad F, Colorado P, Chen CH, Lemmens R, De Marchis GM, Caso V, Masjuan J, Hirano T, Milanov I, Campbell BCV, Mas JL, Connolly SJ, Mundl H, Hart RG; PACIFIC-Stroke Steering Committee and Investigators. Smith EE, et al. Stroke. 2024 Feb;55(2):392-402. doi: 10.1161/STROKEAHA.123.043198. Epub 2024 Jan 4. Stroke. 2024. PMID: 38174569 Clinical Trial.
Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis.
Stefanou MI, Palaiodimou L, Theodorou A, Safouris A, Fischer U, Kelly PJ, Dawson J, Katan M, Katsanos AH, Lambadiari V, Giannopoulos S, Alexandrov AV, Siasos G, Tsivgoulis G. Stefanou MI, et al. Among authors: dawson j. Ther Adv Neurol Disord. 2024 Sep 25;17:17562864241281903. doi: 10.1177/17562864241281903. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39345822 Free PMC article. Review.
2,695 results